Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line

By Qi Hui wei   Shen Zan   Fan Li hong  

Experimental and Therapeutic Medicine, Vol. 2, Iss. 6, 2011-11 ,pp. : 1091-1095

Spandidos Publications

Access to resources Recommend Favorite

Clinical significance of immunohistochemical expression of insulin-like growth factor-1 receptor and matrix metalloproteinase-7 in resected non-small cell lung cancer

By Yamamoto Taketsugu   Oshima Takashi   Yoshihara Kazue   Nishi Teppei   Arai Hiromasa   Inui Kenji   Kaneko Takeshi   Nozawa Akinori   Adachi Hiroyuki   Rino Yasushi   Masuda Munetaka   Imada Toshio  

Experimental and Therapeutic Medicine, Vol. 3, Iss. 5, 2012-05 ,pp. : 797-802

Spandidos Publications

Access to resources Recommend Favorite

Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma

By Ekman Simon   Fröödin Jan-Erik   Harmenberg Johan   Bergman Antonina   Hedlund ÅÅsa   Dahg Pia   Alvfors Carina   Stååhl Birgitta   Bergströöm Stefan   Bergqvist Michael  

Acta Oncologica, Vol. 50, Iss. 3, 2011-04 ,pp. : 441-447

Informa Healthcare

Access to resources Recommend Favorite

Mutational analysis of the insulinlike growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients

By              

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1073-1079

Science Publishers

Access to resources Recommend Favorite

Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo

By      

Oncology Reports, Vol. 31, Iss. 4, 2014-01 ,pp. : 1954-1960

Spandidos Publications

Access to resources Recommend Favorite